Tirzepatide vs Insulin Lispro added to basal insulin in type 2 diabetes

The study evaluated Tirzepatide versus insulin Lispro as adjunctive therapies to insulin Glargine in patients with type 2 diabetes on basal insulin. Weekly Tirzepatide, when compared to prandial insulin as an additional treatment with insulin Glargine, showed efficacy in reducing HbA1c levels and body weight. Notably, Tirzepatide demonstrated these benefits while also resulting in fewer incidents of hypoglycemia. This suggests that Tirzepatide may offer a favorable balance between improved glycemic control and reduced body weight, addressing common concerns associated with diabetes management. The findings highlight the potential of Tirzepatide as a promising option for individuals with type 2 diabetes treated with basal insulin, offering both effectiveness and a more favorable safety profile in comparison to insulin Lispro.